lobbying_activities: 1446337

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1446337	197aaf38-cfac-4551-b2ea-6d7fc798a2e4	Q3	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	3457	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	2013	third_quarter	PHA	Contact concerning FDA authority to manage drug shortages and regulation of pharmacy compounding. Contact concerning HRSA oversight of 340B drug discount program. Communication with the FDA on the REMS program. Contact concerning S. 959, Pharmaceutical Compounding and Quality Accountability Act, (all sections) to address FDA oversight of certain drug compounding entities. Contact concerning HR 3204 (all sections) the Drug Quality and Security Act.	Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE		250000	0	0	2013-10-17T11:57:25.207000-04:00